{"id":414860,"title":"Notice: Guidance Document: Tamper-resistance Formulations of Opioid Drug Products - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-26","captureTimestamp":"2026-01-26T04:36:52.888000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-guidance-document-tamper-resistance-formulations-opioid-drug-products.html","snippet":"Notice: Guidance Document: Tamper-resistance Formulations of Opioid Drug Products March 30, 2016 Our file number: 16-103566-811 Opioid drugs are subject to the Food and Drugs Act and the Controlled Drugs and Substances Act ( CDSA ). An opioid drug may be sold in Canada following…","rawSnapshotUrl":"/api/snapshots/raw/414860","browseUrl":"https://replay.healtharchive.ca/job-6/20260126043652/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-guidance-document-tamper-resistance-formulations-opioid-drug-products.html#ha_snapshot=414860","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}